Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for COPD and IPF Exercise Capacity
NCT03873298Phase 2Unknown
- Sponsor
- Rabin Medical Center
- Start
- Mar 2019
- Primary completion
- Mar 2020
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitric oxide in chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) (2 cohorts), sponsored by Rabin Medical Center. Primary endpoint: Saturation level during the test at 26 minutes. Status: unknown.
02
Drugs
nitric oxide
03
Conditions
chronic obstructive pulmonary disease (COPD)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03873298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873298.